Company profile: Allecra Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical treatments for multi-drug-resistant bacterial infections, including cefepime/enmetazobactam for complicated urinary tract infections and ESBL-producing pathogens, and enmetazobactam, a novel β-lactamase inhibitor with potent activity against Class A serine β-lactamases that enhances the effectiveness of cefepime.
Products and services
- Enmetazobactam: A novel β-lactamase inhibitor with potent activity against Class A serine β-lactamases (ESBL), enhancing cefepime’s efficacy against resistant pathogens, mechanism-based
- Novel β-lactamase inhibitor (Phase 2): Under Phase 2 clinical development to directly tackle emerging multi-drug-resistant bacterial infections by inhibiting β-lactamases, clinical-stage
- Cefepime/Enmetazobactam: Combines cefepime with enmetazobactam to treat complicated urinary tract infections (cUTIs) and overcome ESBL-mediated resistance in pathogens, combination-based
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allecra Therapeutics
Mucosis
HQ: The Netherlands
Website
- Description: Provider of clinical-stage mucosal vaccines delivered needle-free via the nose or mouth, including SynGEM®, an intranasal vaccine candidate to prevent respiratory syncytial virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mucosis company profile →
Bluejay Diagnostics
HQ: United States
Website
- Description: Provider of the Symphony automated diagnostic system using fluorescence immuno-analysis for rapid testing with integrated reagents in single-use cartridges; Symphony cartridges for blood processing and ELISA of specific biomarkers; and the Symphony IL-6 test for near-patient monitoring of disease progression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluejay Diagnostics company profile →
Vaxcyte
HQ: United States
Website
- Description: Provider of vaccines and vaccine development technologies, including VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in adults (FDA Breakthrough Therapy); VAX-31, a 31-valent pneumococcal conjugate candidate; the XpressCF cell-free platform for site-specific conjugation to enhance immunogenicity; and preclinical programs for Group A Strep, periodontitis, and Shigella.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxcyte company profile →
Nuclein
HQ: United States
Website
- Description: Provider of polymerase chain reaction test devices for infectious diseases, offering the DASH Rapid PCR System, a point-of-care platform that performs sample-to-answer PCR tests in 15 minutes for use in CLIA-waived environments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuclein company profile →
Earth Science Tech
HQ: United States
Website
- Description: Provider of science-based biotechnology offerings bringing Nature's Pharmacy to the public, operating RxCompoundStore, a Miami compounding pharmacy licensed in 23 states; Peaks Curative, a telemedicine platform for men's and women's health offering ED products via a proprietary tadalafil gummy; Avenvi, a Miami real estate development firm; and Mister Meds, a Texas wellness-focused pharmacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Earth Science Tech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allecra Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allecra Therapeutics
2.2 - Growth funds investing in similar companies to Allecra Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allecra Therapeutics
4.2 - Public trading comparable groups for Allecra Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →